These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 975718)

  • 21. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma protein binding of salicylate and quinidine in patients with multiple myeloma.
    Perez-Mateo M; Erill S
    Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):168-70. PubMed ID: 447437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium.
    Levy G; Procknal JA; Garrettson LK
    Clin Pharmacol Ther; 1975 Aug; 18(2):210-4. PubMed ID: 1157445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.
    Wosilait WD
    Eur J Clin Pharmacol; 1976 Feb; 9(4):285-90. PubMed ID: 971712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo and in vitro studies on the binding of salicylate to human plasma proteins: evidence for one type of binding site.
    Cham BE; Bochner F; Imhoff DM; Byrne G; Gunsberg M
    J Pharmacol Exp Ther; 1982 Mar; 220(3):648-53. PubMed ID: 7062274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood and saliva salicylate measurement in the monitoring of salicylate therapy.
    Pérez-Mateo M; Erill S; Cabezas R
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):113-5. PubMed ID: 844929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unbound plasma salicylate concentration in rheumatoid arthritis patients.
    Gurwich EL; Raees SM; Skosey J; Niazi S
    Br J Rheumatol; 1984 Feb; 23(1):66-73. PubMed ID: 6697076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Protein binding of salicylates in rheumatoid arthritis].
    Netter P; Monot C; Stalars MC; Mur JM; Royer RJ; Pourel J; Faure G; Martin J; Gaucher A
    Rev Rhum Mal Osteoartic; 1982 May; 49(6):447-52. PubMed ID: 7112023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting drug binding in plasma of elderly patients.
    Wallace S; Whiting B
    Br J Clin Pharmacol; 1976 Apr; 3(2):327-30. PubMed ID: 973967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased protein binding of salicylates in Kawasaki disease.
    Koren G; Silverman E; Sundel R; Edney P; Newburger JW; Klein J; Robieux I; Laxer R; Giesbrecht E; Burns JC
    J Pediatr; 1991 Mar; 118(3):456-9. PubMed ID: 1999792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of heparin injection on plasma protein binding of bilirubin and salicylate in rats.
    Wiegand UW; Levy G
    J Pharm Sci; 1979 Dec; 68(12):1483-6. PubMed ID: 529035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys.
    Viswanathan CT; Levy RH
    J Pharm Sci; 1981 Nov; 70(11):1279-81. PubMed ID: 6795339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction of drug binding defects in uremia in vitro by anion exchange resin treatment.
    Lichtenwalner DM; Suh B; Lorber B; Rudnick MR; Craig WA
    Biochem Pharmacol; 1982 Nov; 31(21):3483-7. PubMed ID: 7150368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Displacement of phenytoin from plasma binding sites by salicylate.
    Fraser DG; Ludden TM; Evens RP; Sutherland EW
    Clin Pharmacol Ther; 1980 Feb; 27(2):165-9. PubMed ID: 7353334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood binding of selezen (imidazole salicylate) in man.
    Zini R; Morin D; Acuto GC; Bianchini C; de Santis F; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):242-9. PubMed ID: 1869346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacology of malnutrition. Part I. Salicylate binding studies using normal serum/plasma and kwashiorkor serum.
    Eyberg C; Moodley GP; Buchanan N
    S Afr Med J; 1974 Dec; 48(61):2564-7. PubMed ID: 4453937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.